Topical application of Cannabis oils and substitutes for the relief of osteoarthritic pai

Phase 2

• Conditions: osteoarthritis; Musculoskeletal - Osteoarthritis

• Registration Number: ACTRN12622000723785
• Lead Sponsor: Westmead Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-05-20
• Last Update Posted: 30 May 2022

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 72

Inclusion Criteria

1. Diagnosis of OA defined by X-ray evidence of joint damage;
2. Age 30–90;
3. Disease duration of 2 years or more;
4. Continued pain in any of the knee, hip, hands or lower lumbar spine joints despite oral
medications;
5. No previous use of oral or smoked cannabinoids for pain management; able to complete
questionnaire;
6. Able to attend outpatient clinic at monitoring and follow-up time points.

Exclusion Criteria

1. History of psychiatric disorder;
2. History of drug dependency;
3. Known sensitivity to cannabinoid agents;
4. History of epilepsy; patient pain explained by fibromyalgia;
5. Recurrent or recent malignancy;
6. Pregnancy or breastfeeding;
7. Change of pain medication in the preceding 4 weeks;
8. Severe renal or liver dysfunction (patient excluded if there is an elevation of baseline liver enzymes);
9. Concomitant medications: Prior or current cannabis use; current use of valproate, clobazam, topiramate, and/or rufinamide.

Study & Design

• Study Type: Interventional
• Study Design: Not specified